Stockreport

MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM Exit - What's Changed [Yahoo! Finance]

MBX Biosciences, Inc.  (MBX) 
PDF In recent months, MBX Biosciences reported positive topline Phase 2 results for its lead drug canvuparatide in hypoparathyroidism and completed an upsized US$200,000,000 [Read more]